Nurix Appoints Rao Chief Medical Officer

Company Nurix Therapeutics Event Type Chief medical officer appointment Modality Targeted protein degradation (oral BTK degrader) Asset Bexobrutideg (NX-5948) Target BTK Disease Area Chronic lymphocytic leukemia and B-cell malignancies Summary Source-gap reconciliation: Nurix appointed Arati V. Rao chief medical officer on November 11, adding clinical-development…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *